Recent Quotes (30 days)

You have no recent quotes
chg | %

Knight Therapeutics Inc  

(Public, CVE:GUD)   Watch this stock  
Find more results for GUD
6.14
Apr 28 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 3.51 - 7.24
Open     -
Vol / Avg. 0.00/822,875.00
Mkt cap 138.83M
P/E     -
Div/yield     -
EPS 0.00
Shares     -
Beta     -
Inst. own     -
Aug 10, 2017
Q2 2017 Knight Therapeutics Inc Earnings Call - Webcast
  

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin 18.51% 312.46%
Operating margin 48.71% 395.17%
EBITD margin - -59.01%
Return on average assets 0.19% 2.26%
Return on average equity 0.19% 2.29%
Employees 25 -
CDP Score - -

Address

3400 de Maisonneuve Blvd W Suite 1055
MONTREAL, QC H3Z 3B8
Canada
+1-514-4844483 (Phone)
+1-514-4814116 (Fax)

Website links

Description

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, Advaxis Family of Products, Ember Family of Products, NeurAxon Family of Products, Antibe Family of Products, Blood Factor Products and VEWS Vascular Early Warning System. In addition, the Company also has a portfolio of branded consumer health products, including Neuragen, Flat Tummy Tea, FOCUSFactor, FLEXISEQ, SEQuaderma, HandMD, UrgentRx, Laboratoire Dr. Renaud, Premiology and Pro-Derm.